CABA

Cabaletta Bio (CABA)

About Cabaletta Bio (CABA)

Cabaletta Bio, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in April 2017 and is headquartered in Philadelphia, PA.

Details

Daily high

$2.51

Daily low

$2.24

Price at open

$2.27

52 Week High

$26.35

52 Week Low

$1.76

Market cap

116.3M

Dividend yield

0.00%

Volume

1.8M

Avg. volume

4.7M

P/E ratio

-1.10

Cabaletta Bio News